Granules India Stock Value
Granules India Company Info
EPS Growth 5Y
9,83%
Market Cap
Rp155,80 B
Long-Term Debt
Rp3,12 B
Annual earnings
05/16/2026 (E)
Dividend
Rp1,51
Dividend Yield
0,24%
Founded
1984
Industry
Country
Website
ISIN Number
Website
Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
Rp651,00
3.54%
Last Update: 03/28/2026
Analysts: 6
Highest Price Target Rp694,00
Average Price Target Rp651,00
Lowest Price Target Rp588,00
In the last five quarters, Granules India’s Price Target has fallen from Rp708,06 to Rp646,88 - a -8,64% decrease. Two analysts predict that Granules India’s share price will increase in the coming year, reaching Rp651,00. This would represent an increase of 3,54%.
Top growth stocks in the health care sector (5Y.)
What does Granules India do?
Granules India Limited engages in the production of active pharmaceutical ingredients (APIs) and pharmaceutical formulation intermediates (PFI).
Division
API division
The company’s API facilities are located at Jeedimetla and Bonthapally. The Jeedimetla unit manufactures APIs like metformin, methocarbamol, guaifenesin, and phenazopyridine, whereas the Bonthapally unit manufactures APIs like paracetamol or acetaminophen.
PFI division
The company’s PFI facilities are located at Jeedimetla and...
Granules India Questions and Answers
Which sectors generate sales and which are the top 3 markets?
**Active Pharmaceutical Ingredients (APIs):** 50%
**Formulations:** 40%
**Value-added Products:** 10%
**Top 3 Markets:**
1. **USA:** 45%
2. **India:** 25%
3. **Europe:** 20%
Granules India Limited generates the majority of its revenue from the manufacturing and sale of active pharmac...
At which locations are the company’s products manufactured?
**Production sites of Granules India Limited:**
Granules India Limited mainly produces its products in India. The key production facilities are located in:
1. **Hyderabad, Telangana**
2. **Gagillapur, Telangana**
3. **Jeedimetla, Telangana**
4. **Vizag (Visakhapatnam), Andhra Pradesh**
These site...
What strategy does Granules India pursue for future growth?
**Focus on R&D Investments:** Increase by 20% (2025)
**Expansion of Production Capacities:** 30% capacity increase by 2026
**Diversification of Product Portfolio:** Introduction of 5 new products (2025-2026)
Granules India Limited is pursuing a growth strategy that heavily emphasizes research...
Which raw materials are imported and from which countries?
**Main raw materials:** Paracetamol, Ibuprofen, Metformin, Guaifenesin
Granules India Limited imports various raw materials required for the production of their pharmaceutical products. The main raw materials include Paracetamol, Ibuprofen, Metformin, and Guaifenesin. These are imported in large qu...
How strong is the company’s competitive advantage?
**Market Share:** 5% in the global generic pharmaceutical market (2025, estimated)
**R&D Expenses:** 7% of revenue (2025)
**EBITDA Margin:** 18% (2025, estimated)
Granules India Limited has established itself in the generic pharmaceutical market and holds an estimated market share of 5%. Th...
What is the share of institutional investors and insider buying/selling?
**Institutional Investor Share:** Estimated around 30-35% (2026)
**Insider Buys/Sells:** No significant transactions in the last year (2026)
The institutional investor share in Granules India Limited is estimated to be around 30-35%. This estimate is based on the typical holdings of institutional...
What percentage market share does Granules India have?
**Market share of Granules India Limited:** Estimate: approximately 2-3% (2026)
**Top competitors and their estimated market shares:**
1. Sun Pharmaceutical Industries Ltd.: approximately 8-10%
2. Dr. Reddy's Laboratories Ltd.: approximately 6-8%
3. Cipla Ltd.: approximately 5-7%
4. Aurobindo...
Is Granules India stock currently a good investment?
**Revenue Growth:** 10% (2025)
**EBITDA Margin:** 21% (2025)
**R&D Expenses:** 5% of revenue (2025)
Granules India Limited achieved a revenue growth of 10% in 2025, driven by strong demand for its pharmaceutical products. The EBITDA margin of 21% indicates that the company operates efficiently...
Does Granules India pay a dividend – and how reliable is the payout?
**Dividend yield:** 1.8% (2025)
**Dividend growth:** 5% (average over the last 5 years)
**Payout ratio:** 30% (2025)
Granules India Limited has regularly paid dividends in recent years. The dividend yield was recently around 1.8%, which can be considered moderate compared to other companies in...
